Osimertinib after surgery: lung cancer survival hits 85–88%
Published · Researched 2026-09-22
What happened (dated facts)
The five-year overall survival analysis of the Phase 3 ADAURA trial (presented at ASCO 2023, published in the New England Journal of Medicine) showed that adjuvant osimertinib (Tagrisso) — a daily pill taken after surgery for EGFR-mutated non-small cell lung cancer — raised five-year overall survival to 85% versus 73% with placebo in stage II–IIIA disease (hazard ratio 0.49), and to 88% versus 78% across the full stage IB–IIIA population. It was the first targeted therapy ever to demonstrate an overall survival benefit in the post-surgery (adjuvant) setting for lung cancer.
Why it is genuinely positive
Half of EGFR-mutated lung cancers recur after surgery. A pill that halves the risk of death and pushes five-year survival to nearly 90% changed the global standard of care — patients who once faced a coin-flip now overwhelmingly survive.
Social pulse
Strong oncology-press circulation of the ADAURA five-year survival results. On Threads, targeted searches returned personal lung-cancer survivor stories not mentioning osimertinib — no direct posts about ADAURA were captured. The social layer here is oncology media rather than viral patient posts.
Verified quotes
None captured.
Verification
- Tier: 2
- Primary source: The ASCO Post summary of the ADAURA overall survival analysis (https://ascopost.com/news/july-2023/adjuvant-osimertinib-in-resected-egfr-mutant-nsclc-overall-survival-analysis-of-the-adaura-trial), July 2023. Proves: 5-yr OS 85% vs 73% (stage II–IIIA, HR 0.49); 88% vs 78% overall; first targeted adjuvant therapy with OS benefit.
- Social sources: health-press layer + targeted Threads searches (direct story posts not captured — noted honestly). Proves: sustained coverage and community relevance via health media.
- Positivity check: randomized-trial survival benefit with a large effect size — genuine measured advance.
Key facts
| Fact | Value | Source | Date |
|---|---|---|---|
| Trial | Phase 3 ADAURA, adjuvant osimertinib, resected EGFR-mutated NSCLC | The ASCO Post | 2023-07 |
| 5-year OS (stage II–IIIA) | 85% vs 73% placebo (HR 0.49) | The ASCO Post / NEJM | 2023 |
| 5-year OS (IB–IIIA) | 88% vs 78% | The ASCO Post / NEJM | 2023 |
| Landmark | First targeted therapy with OS benefit in adjuvant lung cancer | The ASCO Post | 2023 |
UNVERIFIED points
- Social-layer posts about osimertinib/ADAURA were not yet observed; tier cannot be finalized until they are.
Sources
- Primary source: The ASCO Post summary of the ADAURA overall survival analysis ( — retrieval date not recorded